Breast cancer cell lines overexpressing stathmin exhibits decreased sensitivity to paclitaxel and vinblastine22, and a combination of anti-stathmin therapy and taxol has proven more effective than anti-stathmin therapy alone23. Here, STMN1 is linked to breast cancer.